Voyager Therapeutics (VYGR) News Today $3.11 -0.30 (-8.80%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$3.11 0.00 (0.00%) As of 08:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Voyager Therapeutics Presents Promising Tau-Targeting Gene Therapy And Antibody Data At AD/PD 2025April 2 at 8:04 AM | nasdaq.comVoyager Therapeutics, Inc.: Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD 2025March 31, 2025 | finanznachrichten.deVoyager Therapeutics announces new data from two preclinical programsMarch 31, 2025 | markets.businessinsider.comVoyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025March 31, 2025 | globenewswire.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Receives $13.97 Consensus PT from AnalystsMarch 30, 2025 | americanbankingnews.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Recommendation of "Buy" from AnalystsVoyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) has been given an average rating of "Buy" by the nine ratings firms that are covering the stock, MarketBeat reports. Eight investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation oMarch 27, 2025 | marketbeat.comVoyager Therapeutics (NASDAQ:VYGR) Share Price Passes Below 50 Day Moving Average - Here's What HappenedVoyager Therapeutics (NASDAQ:VYGR) Shares Cross Below 50 Day Moving Average - Should You Sell?March 25, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGRMarch 17, 2025 | prnewswire.comHC Wainwright Brokers Boost Earnings Estimates for VYGRVoyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Equities researchers at HC Wainwright upped their Q1 2025 earnings per share (EPS) estimates for Voyager Therapeutics in a research note issued to investors on Thursday, March 13th. HC Wainwright analyst P. Trucchio now anticipates that theMarch 17, 2025 | marketbeat.comWedbush Equities Analysts Reduce Earnings Estimates for VYGRVoyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Equities research analysts at Wedbush decreased their Q1 2025 EPS estimates for Voyager Therapeutics in a research report issued on Wednesday, March 12th. Wedbush analyst Y. Zhong now expects that the company will earn ($0.37) per share forMarch 17, 2025 | marketbeat.comCantor Fitzgerald Issues Positive Outlook for VYGR EarningsVoyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Cantor Fitzgerald increased their FY2025 earnings per share (EPS) estimates for Voyager Therapeutics in a research report issued to clients and investors on Wednesday, March 12th. Cantor Fitzgerald analyst P. Stavropoulos now expects that tMarch 15, 2025 | marketbeat.comCanaccord Genuity Group Issues Pessimistic Forecast for Voyager Therapeutics (NASDAQ:VYGR) Stock PriceCanaccord Genuity Group reduced their price objective on shares of Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating on the stock in a research note on Thursday.March 14, 2025 | marketbeat.comVoyager Therapeutics' (VYGR) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reissued a "buy" rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research note on Thursday.March 14, 2025 | marketbeat.comVoyager Therapeutics price target lowered to $12 from $14 at CanaccordMarch 13, 2025 | markets.businessinsider.comVoyager Therapeutics' (VYGR) Outperform Rating Reaffirmed at WedbushWedbush reaffirmed an "outperform" rating on shares of Voyager Therapeutics in a research note on Wednesday.March 13, 2025 | marketbeat.comVoyager Therapeutics' (VYGR) Overweight Rating Reiterated at Cantor FitzgeraldCantor Fitzgerald reiterated an "overweight" rating on shares of Voyager Therapeutics in a report on Wednesday.March 13, 2025 | marketbeat.comA Glimpse Into The Expert Outlook On Voyager Therapeutics Through 4 AnalystsMarch 12, 2025 | benzinga.comVoyager Therapeutics (NASDAQ:VYGR) Releases Earnings Results, Misses Expectations By $0.24 EPSVoyager Therapeutics (NASDAQ:VYGR - Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.24). Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%.March 12, 2025 | marketbeat.comVoyager Therapeutics price target lowered to $10 from $12 at Wells FargoMarch 12, 2025 | markets.businessinsider.comWells Fargo Reaffirms Their Buy Rating on Voyager Therapeutics (VYGR)March 12, 2025 | markets.businessinsider.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2024 Earnings Call TranscriptMarch 12, 2025 | msn.comVoyager Therapeutics reports Q4 EPS (59c), consensus (35c)March 11, 2025 | markets.businessinsider.comVoyager Therapeutics, Inc. (VYGR) Q4 2024 Earnings Call TranscriptMarch 11, 2025 | seekingalpha.comVoyager Reports Fourth Quarter and Full Year 2024 Financial and Operating ResultsMarch 11, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGRMarch 11, 2025 | prnewswire.comVoyager Therapeutics Q4 2024 Earnings PreviewMarch 10, 2025 | msn.comNASA switches off Voyager instruments to extend life of the two interstellar spacecraft 'Every day could be our last.'March 6, 2025 | msn.comVoyager Therapeutics Announces Fourth Quarter 2024 Conference Call and WebcastMarch 4, 2025 | globenewswire.comVoyager reports promising data for early stage trial in Alzheimer’s disease treatmentMarch 3, 2025 | msn.comVoyager Therapeutics announces data from SAD trial of VY7523March 3, 2025 | markets.businessinsider.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGRMarch 3, 2025 | prnewswire.comVoyager Therapeutics' (VYGR) Buy Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and set a $30.00 price target on shares of Voyager Therapeutics in a report on Monday.March 3, 2025 | marketbeat.comVoyager Therapeutics Reports Positive Topline Data for VY7523 in Alzheimer’s Disease TrialsMarch 3, 2025 | quiverquant.comVoyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer's DiseaseMarch 3, 2025 | globenewswire.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Given Consensus Rating of "Buy" by BrokeragesShares of Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) have been assigned a consensus rating of "Buy" from the nine brokerages that are covering the stock, Marketbeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation and one has given a stroMarch 2, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGRFebruary 25, 2025 | prnewswire.comVoyager Therapeutics to Present at Multiple Upcoming Investor ConferencesFebruary 25, 2025 | globenewswire.comVOYAGER ALERT: Bragar Eagel & Squire, P.C. is Investigating Voyager Therapeutics, Inc. ...February 24, 2025 | gurufocus.comVOYAGER ALERT: Bragar Eagel & Squire, P.C. is Investigating Voyager Therapeutics, Inc. on Behalf of Voyager Stockholders and Encourages Investors to Contact the FirmFebruary 24, 2025 | globenewswire.comVYGR Investors Have Opportunity to Join Voyager Therapeutics, Inc. Fraud Investigation with the Schall Law FirmFebruary 21, 2025 | prnewswire.comVYGR Investors Have Opportunity to Join Voyager Therapeutics, Inc. Fraud Investigation with the Schall Law FirmFebruary 20, 2025 | businesswire.comKirby McInerney LLP Announces Investigation Against Voyager Therapeutics, Inc. (VYGR) on Behalf of InvestorsFebruary 19, 2025 | globenewswire.comVoyager Therapeutics (VYGR) to Release Earnings on WednesdayVoyager Therapeutics (NASDAQ:VYGR) will be releasing earnings before the market opens on Wednesday, February 26.February 19, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGRFebruary 18, 2025 | prnewswire.comResearch Analysts Set Expectations for VYGR FY2025 EarningsVoyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Stock analysts at Wedbush reduced their FY2025 earnings per share (EPS) estimates for shares of Voyager Therapeutics in a report issued on Tuesday, February 11th. Wedbush analyst Y. Zhong now forecasts that the company will earn ($1.12) perFebruary 15, 2025 | marketbeat.comWhat is Wedbush's Estimate for VYGR FY2029 Earnings?Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Equities research analysts at Wedbush issued their FY2029 earnings per share estimates for Voyager Therapeutics in a report issued on Tuesday, February 11th. Wedbush analyst Y. Zhong anticipates that the company will post earnings of ($0.86February 13, 2025 | marketbeat.comVoyager Therapeutics' chief scientific officer sells shares worth $24,087February 12, 2025 | msn.comVoyager Therapeutics COO Robin Swartz sells $30,927 in stockFebruary 12, 2025 | msn.comVoyager Therapeutics' chief legal officer sells $19,393 in stockFebruary 12, 2025 | msn.comVoyager Therapeutics, Inc. (VYGR): A Cheap Biotech Stock to Invest In NowFebruary 12, 2025 | uk.finance.yahoo.com Remove Ads Get Voyager Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter. Email Address VYGR Media Mentions By Week VYGR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VYGR News Sentiment▼0.500.61▲Average Medical News Sentiment VYGR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VYGR Articles This Week▼55▲VYGR Articles Average Week Remove Ads Get Voyager Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Intellia Therapeutics News Anavex Life Sciences News Gyre Therapeutics News Rocket Pharmaceuticals News Bicara Therapeutics News LENZ Therapeutics News Cronos Group News Cogent Biosciences News Prothena News AbCellera Biologics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VYGR) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredNearly $3 Trillion Gone…Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow you could profit from Elon’s latest AI breakthroughEvery single one of Elon's projects minted an entire new class of millionaires. And xAI could be next in li...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Voyager Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Voyager Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VYGR Stock Free VYGR Stock Alerts